CORT
Corcept Therapeutics Incorporated
Biotechnology · Healthcare · United States
85.95
close · 2026-10-29
value
20
cheaper than peers20
quality
95
stronger fundamentals95
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 20.48× | 53 |
| price to sales | 14.05× | 47 |
| price to book | 13.14× | 18 |
| EV to EBITDA | 1431.28× | 1 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.3% | 92 |
| operating margin | 16.1% | 85 |
| return on equity | 8.2% | 84 |
| revenue growth | 31.7% | 57 |
4 of 4 measures available
Facts
| market cap | $9B |
| free cash flow | $77.4M |
| employees | 730 |
| first trade | 2004-04-14 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | 0.82 | 1.23 | 0.94 | 0.87 | not reported |
| free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | not reported |
| net income | $99.7M | $141.2M | $106.1M | $101.4M | not reported |
| revenue | $761.4M | $675.0M | $482.4M | $401.9M | not reported |
| unusual items | not reported | $0 | $0 | $0 | $0 |